Corporate Banner
Satellite Banner
Cell Culture
Scientific Community
Become a Member | Sign in
Home>News>This Article

Artificial Liver Cells Win their Creator Prize for their Potential to Reduce Animal Experiments

Published: Friday, March 02, 2012
Last Updated: Friday, March 02, 2012
Bookmark and Share
Cambridge researchers recognised with a national prize by the National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs).

Producing liver cells that demonstrate inherited liver diseases from human skin cells has earned Dr Ludovic Vallier from the University of Cambridge a major prize from the National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs). These cells, known as human induced pluripotent stem cells (hIPSCs), have already attracted attention for the possibilities they offer to regenerate damaged tissues and organs. But it is their potential to reduce the number of animals used for screening potential drug treatments that led to Dr Vallier receiving the Centre’s 3Rs prize for 2011.

The prize, sponsored by GlaxoSmithKline, of a £2,000 personal award and a £18,000 research grant, is for the scientific paper published in the last three years that contributes most to the advancement of the 3Rs (Replacement, Reduction and Refinement). Dr Vallier’s winning paper was published in The Journal of Clinical Investigation in 2010. He received his prize from Professor Paul Matthews OBE of GlaxoSmithKline at the NC3Rs Annual Science Review Meeting in London on 28 February.

Human liver cells (hepatocytes) cannot be grown in the laboratory and differences between rodents and humans mean that it is rarely possible to recreate the human disease completely in mice or rats or to use cultures of rat or mouse liver cells. Dr Vallier’s team took skin cells (dermal fibroblasts) from seven patients with a variety of inherited liver diseases and three healthy individuals (the controls). They then reprogrammed cells from the skin samples back into stem cells. These stem cells were then used to generate liver cells which mimicked a broad range of liver diseases – and to create ‘healthy’ liver cells from the control group.

These hIPSC-generated liver cells can provide in vitro models for basic research and drug discovery. Their use has already reduced the use of animals needed for the production of liver cells in the laboratories that have adopted this technology. The cells could also transform the investigation of chemical/drug-induced liver injury, a major concern for the chemical and pharmaceutical industries, by reducing dependence on animal testing.

Sharmila Nebhrajani, chief executive of the Association of Medical Research Charities (AMRC) said:  “Charities invest over £1bn in health research each year, money raised by patients, their families and carers to understand the causes of disease and search for possible cures. Using 3Rs techniques, these prize winning researchers are bringing real hope to people with liver disease. What’s more – they are developing new methods for medical research which should benefit patients with all kinds of conditions.”

On presenting Dr Vallier with his prize, Professor Paul Matthews, Vice-President for Imaging at GlaxoSmithKline, commented: “Ludovic Vallier’s innovative study describes the development and validation of a method to produce cells similar to those in a human liver. Such cells could replace animals for some types of early drug testing and could also help us to predict adverse clinical reactions. Using these cells for drug testing could be transformative.  Ludovic and his colleagues have well illustrated how addressing the 3Rs converges with improving the quality of science!”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

‘Mini-Lungs’ Grown To Aid The Study Of Cystic Fibrosis
'Mini-lungs’ have been created using stem cells derived from skin cells of patients with cystic fibrosis.
Thursday, March 19, 2015
Critical Stage of Embryonic Development Now Observable
Scientists now able to view critical aspects of mammalian embryonic development using new technique.
Wednesday, February 15, 2012
Scientific News
Personalized Drug Screening for Multiple Myeloma Patients
A personalized method for testing the effectiveness of drugs that treat multiple myeloma may predict quickly and more accurately the best treatments for individual patients with the bone marrow cancer.
Cancer-Fighting Tomato Component Traced
The metabolic pathway associated with lycopene, the bioactive red pigment found in tomatoes, has been traced by researchers at the University of Illinois.
Some Gut Microbes May Be Keystones of Health
University of Oregon scientists have found that strength in numbers doesn’t hold true for microbes in the intestines. A minority population of the right type might hold the key to regulating good health.
The Life Story of Stem Cells
A model analyses the development of stem cell numbers in the human body.
Novel Stem Cell Line Avoids Risk of Introducing Transplanted Tumors
Progenitor cells might eventually be used to repair or rebuild damaged or destroyed organs.
Tissue Engineers Recruit Cells to Make Their Own Strong Matrix
Extracellular matrix is the material that gives tissues their strength and stretch. It’s been hard to make well in the lab, but a Brown University team reports new success. The key was creating a culture environment that guided cells to make ECM themselves.
Towards Patient-Specific Drug Screening
A new breakthrough by the 3D stem cell printing team at Heriot-Watt could pave the way to individually tailored drug testing regimes, both reducing the need for animal testing and ensuring that patients receive drugs which are most effective for their individual needs.
Artificial Kidney Research Gets A Boost
Development of a surgically implantable, artificial kidney — a promising alternative to kidney transplantation or dialysis for people with end-stage kidney disease — has received a $6 million boost.
Improving the Efficiency of Red Blood Cell Production
Study points to way of significantly reducing cost of laboratory-produced cells.
Blood T Cells Are Resistant to HIV’s Primary Death Pathway
Scientists say HIV research should focus on lymphoid tissue, not blood cells.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos